Allogeneic hematopoietic stem cell transplantation in patients with sickle cell disease with alternative donors – Case series

Authors

  • Marlene Micaela Sepich Instituto Universitario de Ciencias Biomédicas de Córdoba – Hospital Privado Universitario de Córdoba – Departamento de Hematología y Oncología, Programa de Trasplante de Médula Ósea y Terapia Celular – Córdoba – Argentina. https://orcid.org/0009-0003-6142-9820
  • Milagros Lopez Orozco Instituto Universitario de Ciencias Biomédicas de Córdoba – Hospital Privado Universitario de Córdoba – Departamento de Hematología y Oncología, Programa de Trasplante de Médula Ósea y Terapia Celular – Córdoba – Argentina. https://orcid.org/0009-0003-2261-6500
  • Gonzalo Ariel Ferini Hospital Italiano – Buenos Aires – Argentina. https://orcid.org/0000-0002-0463-5615
  • Martin Milanesio Instituto Universitario de Ciencias Biomédicas de Córdoba – Hospital Privado Universitario de Córdoba – Departamento de Hematología y Oncología, Programa de Trasplante de Médula Ósea y Terapia Celular – Córdoba – Argentina. https://orcid.org/0000-0002-9521-3601
  • Maria Emilia Mas Instituto Universitario de Ciencias Biomédicas de Córdoba – Hospital Privado Universitario de Córdoba – Departamento de Hematología y Oncología, Programa de Trasplante de Médula Ósea y Terapia Celular – Córdoba – Argentina. https://orcid.org/0009-0000-8053-0084
  • Jorge Alberto Arbelbide Hospital Italiano – Buenos Aires – Argentina. https://orcid.org/0000-0003-2367-6161
  • Ana Lisa Basquiera Instituto Universitario de Ciencias Biomédicas de Córdoba – Hospital Privado Universitario de Córdoba – Departamento de Hematología y Oncología, Programa de Trasplante de Médula Ósea y Terapia Celular – Córdoba – Argentina. https://orcid.org/0000-0001-9892-5543

DOI:

https://doi.org/10.46765/2675-374X.2025v7n1e313

Keywords:

Sickle cell disease, Allogeneic transplant, Graft-versus-host disease (GVHD), Hemoglobinopathy

Abstract

Sickle cell disease is a hereditary hemoglobinopathy characterized by the presence of hemoglobin S (HbS), which leads to erythrocyte deformation, promotes hemolysis, and causes recurrent vaso-occlusive crises with multisystem involvement. Therapeutic options include pharmacological agents such as hydroxyurea, chronic blood transfusions, and, in selected cases, allogeneic hematopoietic stem cell transplantation (allo-HSCT), which remains the only curative option currently available. Here, we describe four cases that underwent allo-HSCT due to severe disease-related complications, highlighting the effectiveness of the procedure in appropriately selected cases.

References

1. Ingram VM. Gene mutations in human haemoglobin: the chemical difference between normal and sickle cell haemoglobin. Nature. 1957;180(4581):326-8. https://doi.org/10.1038/180326a0 DOI: https://doi.org/10.1038/180326a0

2. Rees DC, Williams TN, Gladwin MT. Sickle-cell disease. Lancet. 2010;376(9757):2018-31. https://doi. org/10.1016/S0140-6736(10)61029-X DOI: https://doi.org/10.1016/S0140-6736(10)61029-X

3. Piel FB, Patil AP, Howes RE, Nyangiri OA, Gething PW, Dewi M, et al. Global epidemiology of sickle haemoglobin in neonates: a contemporary geostatistical model-based map and population estimates. Lancet. 2013;381(9861):142-51. https://doi.org/10.1016/S0140-6736(12)61229-X DOI: https://doi.org/10.1016/S0140-6736(12)61229-X

4. Serjeant GR. The natural history of sickle cell disease. Cold Spring Harb Perspect Med. 2013;3(10): a011783. https://doi.org/10.1101/cshperspect.a011783 DOI: https://doi.org/10.1101/cshperspect.a011783

5. Jiao B, Johnson KM, Ramsey SD, Bender MA, Devine B, Basu A. Long-term survival with sickle cell disease: a nationwide cohort study of Medicare and Medicaid beneficiaries. Blood Adv. 2023;7(13):3276-83. https://doi.org/10.1182/bloodadvances.2022009202 DOI: https://doi.org/10.1182/bloodadvances.2022009202

6. Cancado RD, Costa FF, Lobo C, Migliavaca CB, Falavigna M, Souza Filho HCR, et al. Estimated mortality rates of individuals with sickle cell disease in Brazil: real-world evidence. Blood Adv. 2023;7(15):3783-92. https://doi.org/10.1182/bloodadvances.2022008938 DOI: https://doi.org/10.1182/bloodadvances.2022008938

7. Nagel RL, Fabry ME, Steinberg MH. The paradox of hemoglobin SC disease. Blood Rev. 2003;17(3):167-78. https://doi.org/10.1016/S0268-960X(03)00003-1 DOI: https://doi.org/10.1016/S0268-960X(03)00003-1

8. Gluckman E, Cappelli B, Bernaudin F, Labopin M, Volt F, Carreras J, et al. Sickle cell disease: an international survey of results of HLA-identical sibling hematopoietic stem cell transplantation. Blood. 2017;129(11): 1548-56. https://doi.org/10.1182/blood-2016-10-745711 DOI: https://doi.org/10.1182/blood-2016-10-745711

9. Bhatia M, Kolva E, Cimini L, Jin Z, Satwani P, Savone M, et al. Health-related quality of life after allogeneic hematopoietic stem cell transplantation for sickle cell disease. Biol Blood Marrow Transplant. 2015;21(4):666-72. https://doi.org/10.1016/j.bbmt.2014.12.007 DOI: https://doi.org/10.1016/j.bbmt.2014.12.007

10. Dovern E, Nijland S, Braamse AMJ, van Muilekom MM, Suijk EMJ, Hoogendoorn GM, et al. Changes in the quality of life of adults with sickle cell disease following allogeneic stem cell transplantation: A mixedmethods, prospective cohort study. Hemasphere. 2025;9(3):e70100. https://doi.org/10.1002/hem3.70100 DOI: https://doi.org/10.1002/hem3.70100

11. Walters MC, Hardy K, Edwards S, Adamkiewicz T, Barkovich J, Bernaudin F, et al. Pulmonary, gonadal, and central nervous system status after bone marrow transplantation for sickle cell disease. Biol Blood Marrow Transplant. 2010;16(2):263-72. https://doi.org/10.1016/j.bbmt.2009.10.005 DOI: https://doi.org/10.1016/j.bbmt.2009.10.005

12. Bernaudin F, Socie G, Kuentz M, Chevret S, Duval M, Bertrand Y, et al. Long-term results of related myeloablative stem-cell transplantation to cure sickle cell disease. Blood. 2007;110(7):2749-56. https://doi.org/10.1182/blood-2007-03-079665 DOI: https://doi.org/10.1182/blood-2007-03-079665

13. Bolanos-Meade J, Fuchs EJ, Luznik L, Lanzkron SM, Gamper CJ, Jones RJ, et al. HLA-haploidentical bone marrow transplantation with posttransplant cyclophosphamide expands the donor pool for patients with sickle cell disease. Blood. 2012;120(22):4285-91. https://doi.org/10.1182/blood-2012-07-438408 DOI: https://doi.org/10.1182/blood-2012-07-438408

14. Luznik L, O’Donnell PV, Fuchs EJ. Post-transplantation cyclophosphamide for tolerance induction in HLAhaploidentical bone marrow transplantation. Semin Oncol. 2012;39(6):683-93. https://doi.org/10.1053/j.seminoncol.2012.09.005 DOI: https://doi.org/10.1053/j.seminoncol.2012.09.005

15. Bolanos-Meade J, Cooke KR, Gamper CJ, Ali SA, Ambinder RF, Borrello IM, et al. Effect of increased dose of total body irradiation on graft failure associated with HLA-haploidentical transplantation in patients with severe haemoglobinopathies: a prospective clinical trial. Lancet Haematol. 2019;6(4):e183-e93. https://doi.org/10.1016/S2352-3026(19)30031-6 DOI: https://doi.org/10.1016/S2352-3026(19)30031-6

16. Anurathapan U, Hongeng S, Pakakasama S, Sirachainan N, Songdej D, Chuansumrit A, et al. Hematopoietic stem cell transplantation for homozygous beta-thalassemia and beta-thalassemia/hemoglobin E patients from haploidentical donors. Bone Marrow Transplant. 2016; 51(6): 813-8. https://doi.org/10.1038/bmt.2016.7 DOI: https://doi.org/10.1038/bmt.2016.7

17. Rostami T, Rad S, Rostami MR, Mirhosseini SA, Alemi H, Khavandgar N, et al. Hematopoietic stem cell transplantation in sickle cell disease: a multidimentional review. Cell Transplant. 2024;33. https://doi.org/10.1177/09636897241246351 DOI: https://doi.org/10.1177/09636897241246351

18. Wingard JR, Majhail NS, Brazauskas R, Wang Z, Sobocinski KA, Jacobsohn D, et al. Long-term survival and late deaths after allogeneic hematopoietic cell transplantation. J Clin Oncol. 2011;29(16):2230-9. https://doi.org/10.1200/JCO.2010.33.7212 DOI: https://doi.org/10.1200/JCO.2010.33.7212

19. Cronin RM, Wuichet K, Ghafuri DL, Hodges B, Chopra M, He J, et al. Creating an automated contemporaneous cohort in sickle cell anemia to predict survival after disease-modifying therapy. Blood Adv. 2023;7(15): 3775-82. https://doi.org/10.1182/bloodadvances.2022008692 DOI: https://doi.org/10.1182/bloodadvances.2022008692

20. Guilcher GMT, Truong TH, Saraf SL, Joseph JJ, Rondelli D, Hsieh MM. Curative therapies: Allogeneic hematopoietic cell transplantation from matched related donors using myeloablative, reduced intensity, and nonmyeloablative conditioning in sickle cell disease. Semin Hematol. 2018;55(2):87-93. https://doi.org/10.1053/j.seminhematol.2018.04.011 DOI: https://doi.org/10.1053/j.seminhematol.2018.04.011

21. Iqbal M, Reljic T, Corbacioglu S, de la Fuente J, Gluckman E, Kumar A, et al. Systematic review/meta-analysis on efficacy of allogeneic hematopoietic cell transplantation in sickle cell disease: an international effort on behalf of the pediatric diseases working party of European Society for Blood and Marrow Transplantation and the Sickle Cell Transplantation International Consortium. Transplant Cell Ther. 2021;27(2):167e1-e12. https://doi.org/10.1016/j.jtct.2020.10.007 DOI: https://doi.org/10.1016/j.jtct.2020.10.007

22. St Martin A, Hebert KM, Serret-Larmande A, Jouhet V, Hughes E, Stedman J, et al. Long-term survival after hematopoietic cell transplant for sickle cell disease compared to the United States population. Transplant Cell Ther. 2022;28(6):325e1-e7. https://doi.org/10.1016/j.jtct.2022.03.014 DOI: https://doi.org/10.1016/j.jtct.2022.03.014

23. Garban F, Makowski C, Bulabois CE, Bouillet L, Meunier M. High-risk allogeneic stem cells transplantation in advanced age patients with uncontrolled sickle cell disease. Eur J Intern Med. 2025;134:154-6. https://doi.org/10.1016/j.ejim.2024.11.017 DOI: https://doi.org/10.1016/j.ejim.2024.11.017

24. Damlaj M, Alahmari B, Alaskar A, Alhejazi A, Alsadi H, Ahmed M, et al. Favorable outcome of nonmyeloablative allogeneic transplantation in adult patients with severe sickle cell disease: A single center experience of 200 patients. Am J Hematol. 2024;99(6):1023-30. https://doi.org/10.1002/ajh.27295 DOI: https://doi.org/10.1002/ajh.27295

25. Penack O, Marchetti M, Aljurf M, Arat M, Bonifazi F, Duarte RF, et al. Prophylaxis and management of graft versus-host disease after stem-cell transplantation for haematological malignancies: updated consensus recommendations of the European Society for Blood and Marrow Transplantation. Lancet Haematol. 2024;11(2):e147-e59. https://doi.org/10.1016/S2352-3026(23)00342-3 DOI: https://doi.org/10.1016/S2352-3026(23)00342-3

26. Flowers ME, Inamoto Y, Carpenter PA, Lee SJ, Kiem HP, Petersdorf EW, et al. Comparative analysis of risk factors for acute graft-versus-host disease and for chronic graft-versus-host disease according to National Institutes of Health consensus criteria. Blood. 2011;117(11):3214-9. https://doi.org/10.1182/blood-2010-08-302109 DOI: https://doi.org/10.1182/blood-2010-08-302109

27. Kurian TJ, Irizarry Gatell V, Adams W, Tsai SB, Smith SE, Stiff PJ, et al. Impact of graft composition on graf tversus-host disease in peripheral blood HLA-identical sibling transplants: protective role of CD8 cell dose. Blood. 2018;132(Supplement 1):5719. https://doi.org/10.1182/blood-2018-99-115557 DOI: https://doi.org/10.1182/blood-2018-99-115557

28. Balaguer-Rosello A, Gil-Perotin S, Montoro J, Bataller L, Lamas B, Villalba M, et al. Reduced incidence of neurologic complications after allogeneic hematopoietic stem cell transplantation with calcineurinfree graft-versus-host disease prophylaxis. Transplant Cell Ther. 023;29(10):610e1-e12. https://doi.org/10.1016/j.jtct.2023.07.008 DOI: https://doi.org/10.1016/j.jtct.2023.07.008

29. Elmariah H, Otoukesh S, Kumar A, Ali H, Arslan S, Shouse G, et al. Sirolimus Is an acceptable alternative to tacrolimus for graft-versus-host disease prophylaxis after haploidentical peripheral blood stem cell transplantation with post-transplantation cyclophosphamide. Transplant Cell Ther. 2024;30(2):229e1-e11.https://doi.org/10.1016/j.jtct.2023.11.010 DOI: https://doi.org/10.1016/j.jtct.2023.11.010

30. Ibrahimova A, Khoury R, Jodele S, Grimley M, Davies SM, Khandelwal P. Abatacept for acute graft versus host disease prophylaxis in children with sickle cell disease patients undergoing HLA-identical sibling hematopoietic stem cell transplantation. Bone Marrow Transplant. 2025;60(8):1102-7. https://doi.org/10.1038/s41409-025-02601-6 DOI: https://doi.org/10.1038/s41409-025-02601-6

31. Pawlowska AB, Cheng JC, Karras NA, Sun W, Wang LD, Bell AD, et al. HLA Haploidentical stem cell transplant with pretransplant immunosuppression for patients with sickle cell disease. Biol Blood Marrow Transplant. 2018;24(1):185-9. https://doi.org/10.1016/j.bbmt.2017.08.039 DOI: https://doi.org/10.1016/j.bbmt.2017.08.039

32. Dovern E, Aydin M, Hazenberg MD, Tang MW, Suijk EM, Hoogendoorn GM, et al. Azathioprine/ hydroxyurea preconditioning prior to nonmyeloablative matched sibling donor hematopoietic stem cell transplantation in adults with sickle cell disease: A prospective observational cohort study. Am J Hematol. 2024;99(8):1523-31. https://doi.org/10.1002/ajh.27360 DOI: https://doi.org/10.1002/ajh.27360

33. Kassim AA, Walters MC, Eapen M, Smith M, Logan BR, Solh M, et al. Haploidentical bone marrow transplantation for sickle cell disease. NEJM Evid. 2025;4(3). https://doi.org/10.1056/EVIDoa2400192 DOI: https://doi.org/10.1056/EVIDoa2400192

34. Ciurea SO, de Lima M, Cano P, Korbling M, Giralt S, Shpall EJ, et al. High risk of graft failure in patients with anti-HLA antibodies undergoing haploidentical stem-cell transplantation. Transplantation. 2009; 88(8): 1019-24. https://doi.org/10.1097/TP.0b013e3181b9d710 DOI: https://doi.org/10.1097/TP.0b013e3181b9d710

35. Lima ACM, Getz J, do Amaral GB, Loth G, Funke VAM, Nabhan SK, et al. Donor-specific HLA antibodies are associated with graft failure and delayed hematologic recovery after unrelated donor hematopoietic cell transplantation. Transplant Cell Ther. 2023;29(8):493e1-e10. https://doi.org/10.1016/j.jtct.2023.05.014 DOI: https://doi.org/10.1016/j.jtct.2023.05.014

36. Bayoumy M, Raffa EH, Alharbi AA, Abosoudah I, Orabe A, Altrabolsi H, et al. Outcomes of hematopoietic stem cell transplantation in children with sickle cell disease: does donor sickle cell trait status matter? Bone Marrow Transplant. 2025;60(7):1060-1. https://doi.org/10.1038/s41409-025-02572-8 DOI: https://doi.org/10.1038/s41409-025-02572-8

37. Ramos Martinez A, Pintos Pascual I, Munez Rubio E. Infections in immunocompromised patients (II). The transplanted patient. Medicine (Madr). 2018;12(55):3245-52. https://doi.org/10.1016/j.med.2018.04.011 DOI: https://doi.org/10.1016/j.med.2018.04.011

38. Neuerburg CKF, Schmitz F, Schmitz MT, Rehnelt S, Schumacher M, Parcina M, et al. Antibiotic prophylaxis during allogeneic stem cell transplantation – A comprehensive single center retrospective analysis. Transplant Cell Ther. 2024;30(12):1195e1- e13. https://doi.org/10.1016/j.jtct.2024.09.011 DOI: https://doi.org/10.1016/j.jtct.2024.09.011

39. Grimbly C, Escagedo PD, Jaremko JL, Bruce A, Alos N, Robinson ME, et al. Sickle cell bone disease and response to intravenous bisphosphonates in children. Osteoporos Int. 2022;33(11):2397-408. https://doi.org/10.1007/s00198-022-06455-2 DOI: https://doi.org/10.1007/s00198-022-06455-2

40. John TD, Namazzi R, Chirande L, Tubman VN. Global perspectives on cellular therapy for children with sickle cell disease. Curr Opin Hematol. 2022;29(6):275-80. https://doi.org/10.1097/MOH.0000000000000738 DOI: https://doi.org/10.1097/MOH.0000000000000738

41. Ally M, Balandya E. Current challenges and new approaches to implementing optimal management of sickle cell disease in sub-Saharan Africa. Semin Hematol. 2023;60(4):192-9. https://doi.org/10.1053/j.seminhematol.2023.08.002 DOI: https://doi.org/10.1053/j.seminhematol.2023.08.002

42. Figueiroa HR, Zecchin VG, da Silva AMPdS, Cela MF, Lee MLDM, Romagnol FT, et al. Hematopoietic stem cell transplantation in sickle cell disease, experience of a Brazilian private service. Blood. 2024; 144 (Supplement 1): 7322. https://doi.org/10.1182/blood-2024-209967 DOI: https://doi.org/10.1182/blood-2024-209967

43. Simoes BP, Navarro GB, Pieroni F, Darrigo LG, Jr., Moraes D, Stracieri ABP, et al. Allogeneic stem cell transplantation for sickle cell disease in Brazil: the time is now! Blood. 2011;118(21):1064. https://doi.org/10.1182/blood.V118.21.1064.1064 DOI: https://doi.org/10.1182/blood.V118.21.1064.1064

44. Simoes BP, Pieroni F, Costa T, Barros GN, Darrigo G, Jr., Grecco CS, et al. Allogenic bone narrow transplantation in sickle-cell diseases. Rev Assoc Med Bras. 2016;62(Suppl 1):16-22. https://doi.org/10.1590/1806-9282.62.suppl1.16 DOI: https://doi.org/10.1590/1806-9282.62.suppl1.16

45. Kapoor S, Little JA, Pecker LH. Advances in the treatment of sickle cell disease. Mayo Clin Proc. 2018; 93(12):1810-24. https://doi.org/10.1016/j.mayocp.2018.08.001 DOI: https://doi.org/10.1016/j.mayocp.2018.08.001

Downloads

Published

04/15/2026

How to Cite

Sepich, M. M., Orozco, M. L., Ferini, G. A., Milanesio, M., Mas, M. E., Arbelbide, J. A., & Basquiera, A. L. (2026). Allogeneic hematopoietic stem cell transplantation in patients with sickle cell disease with alternative donors – Case series. JOURNAL OF BONE MARROW TRANSPLANTATION AND CELLULAR THERAPY, 7(1). https://doi.org/10.46765/2675-374X.2025v7n1e313

Issue

Vol. 7 No. 1 (2026): Journal of Bone Marrow Transplantation and Cellular Therapy

Section

Case reports

License

Copyright (c) 2026 Marlene Micaela Sepich, Milagros Lopez Orozco, Gonzalo Ariel Ferini, Martin Milanesio, Maria Emilia Mas, Jorge Alberto Arbelbide, Ana Lisa Basquiera

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.